TS-060782 — Problem Statement: Diagnosis of arterial occlusion and an associated stroke can be lengthy, delaying patient access to treatment. As large vessel occlusions account for 24 to 46% of acute ischemic strokes and may require treatment in a comprehensive stroke center, early diagnosis is key. Solution:…

TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics of salmonellosis, as well as small molecule inhibitors of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy of FraB inhibitors.

TS-059578 — A novel biomarker for the early identification of cardiac damage, including chemotherapy-induced cardiotoxicity.

TS-059537 — An untargeted NMR-based metabolomics approach to identify metabolic compounds as signatures of bacterial joint infections and methods for the treatment and prevention thereof.

TS-058669 — A knock-in mouse model carrying a modified dopamine transporter that is resistant to cocaine inhibition and thus showing no rewarding cocaine effects.

TS-058668 — A knock-in mouse model with a modified norepinephrine transporter carrying triple mutations that makes the transporter protein resistant to cocaine and antidepressants.

TS-058084 — A rabbit model has been created for Duchenne Muscular Dystrophy (DMD) that more closely resembles the effects experienced in humans while being more cost effective compared to larger animal models.

TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.

TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).

TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.

TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.

TS-055268 — The laboratory of Dr. Rosa Lapalombella in collaboration with Dr. James Blachly at The Ohio State University has developed a mouse model of spontaneous Chronic Lymphocytic Leukemia.

TS-054471 — Knee templating is used as part of the pre-operative planning for knee replacement to determine the best fit for an implant. The current assistive devices used to determine fit are unreliable and inaccurate for proper patient fit. A new device is suggested to overcome these limitations.

TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.

TS-051298 — MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression post-transcriptionally. Their sequences differ, but their lengths fall within a range of ~20-23 nucleotides because the precursor miRNAs are processed by Dicer. Dicer cleaves long double-stranded RNA (dsRNA) molecules into s…

TS-050433 — A gene therapy solution for Usher Syndrome Type 1F.

TS-050296 — A sequencing-based diagnostic assay for SARS-CoV-2 with sensors of immune activation and the viral microbiota.

TS-050245 — An integrated platform with multiple sensing modalities to actively orchestrate antimicrobial activity and wound healing.

TS-050238 — Methods of purifying proteins that can be used in various applications such as drug delivery, bioimaging and hemolysis treatment.

TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity